Literature DB >> 11859410

Inflammatory cytokine regulation of TRAIL-mediated apoptosis in thyroid epithelial cells.

J D Bretz1, E Mezosi, T J Giordano, P G Gauger, N W Thompson, J R Baker.   

Abstract

Death receptor-mediated apoptosis has been implicated in target organ destruction in chronic autoimmune thyroiditis. Depending on the circumstances, inflammatory cytokines such as IL-1, TNF and IFNgamma have been shown to contribute to either the induction, progression or inhibition of this disease. Here we demonstrate that the death ligand TRAIL can induce apoptosis in primary, normal, thyroid epithelial cells under physiologically relevant conditions, specifically, treatment with the combination of inflammatory cytokines IL-1beta and TNFalpha. In contrast, IFNgamma is capable of blocking TRAIL-induced apoptosis in these cells. This regulation of TRAIL-mediated apoptosis by inflammatory cytokines appears to be due to alterations of cell surface expression of TRAIL receptor DR5 and not DR4. We also show the in vivo presence of TRAIL and TRAIL receptors DR5 and DcR1 in both normal and inflamed thyroids. Our data suggests TRAIL-mediated apoptosis may contribute to target organ destruction in chronic autoimmune thyroiditis.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 11859410     DOI: 10.1038/sj.cdd.4400965

Source DB:  PubMed          Journal:  Cell Death Differ        ISSN: 1350-9047            Impact factor:   15.828


  12 in total

1.  Localization of TRAIL/TRAILR in fetal pancreas.

Authors:  Li-Hua Chen; Xue-Song Liu; Wen-Yong Wang; Wei-Ning Han; Bo-Rong Pan; Bo-Quan Jin
Journal:  World J Gastroenterol       Date:  2003-02       Impact factor: 5.742

2.  Decreasing TNF-alpha results in less fibrosis and earlier resolution of granulomatous experimental autoimmune thyroiditis.

Authors:  Kemin Chen; Yongzhong Wei; Gordon C Sharp; Helen Braley-Mullen
Journal:  J Leukoc Biol       Date:  2006-10-17       Impact factor: 4.962

Review 3.  The promise of TRAIL--potential and risks of a novel anticancer therapy.

Authors:  Ronald Koschny; Henning Walczak; Tom M Ganten
Journal:  J Mol Med (Berl)       Date:  2007-04-17       Impact factor: 4.599

4.  Alveolar epithelial cells in idiopathic pulmonary fibrosis display upregulation of TRAIL, DR4 and DR5 expression with simultaneous preferential over-expression of pro-apoptotic marker p53.

Authors:  Khondoker M Akram; Nicola J Lomas; Nicholas R Forsyth; Monica A Spiteri
Journal:  Int J Clin Exp Pathol       Date:  2014-01-15

5.  A critical role for TRAIL in resolution of granulomatous experimental autoimmune thyroiditis.

Authors:  Y Fang; G C Sharp; H Yagita; H Braley-Mullen
Journal:  J Pathol       Date:  2008-12       Impact factor: 7.996

Review 6.  Autophagy in thyroid cancer: present knowledge and future perspectives.

Authors:  Romana T Netea-Maier; Viola Klück; Theo S Plantinga; Johannes W A Smit
Journal:  Front Endocrinol (Lausanne)       Date:  2015-02-18       Impact factor: 5.555

7.  Novel treatment option for MUC16-positive malignancies with the targeted TRAIL-based fusion protein Meso-TR3.

Authors:  Gunjal Garg; Jesse Gibbs; Brian Belt; Matthew A Powell; David G Mutch; Peter Goedegebuure; Lynne Collins; David Piwnica-Worms; William G Hawkins; Dirk Spitzer
Journal:  BMC Cancer       Date:  2014-01-21       Impact factor: 4.430

8.  Cowden syndrome-associated germline succinate dehydrogenase complex subunit D (SDHD) variants cause PTEN-mediated down-regulation of autophagy in thyroid cancer cells.

Authors:  Wanfeng Yu; Ying Ni; Motoyasu Saji; Matthew D Ringel; Ritika Jaini; Charis Eng
Journal:  Hum Mol Genet       Date:  2017-04-01       Impact factor: 6.150

Review 9.  Modulation of inflammation by autophagy: Consequences for human disease.

Authors:  Romana T Netea-Maier; Theo S Plantinga; Frank L van de Veerdonk; Johannes W Smit; Mihai G Netea
Journal:  Autophagy       Date:  2015-07-29       Impact factor: 16.016

10.  Mesothelin's minimal MUC16 binding moiety converts TR3 into a potent cancer therapeutic via hierarchical binding events at the plasma membrane.

Authors:  Yang Su; Katharina Tatzel; Xuejun Wang; Brian Belt; Pratibha Binder; Lindsay Kuroki; Matthew A Powell; David G Mutch; William G Hawkins; Dirk Spitzer
Journal:  Oncotarget       Date:  2016-05-24
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.